Topics

Novel Molecular Markers at Forefront of NSCLC Research

16:54 EST 28 Nov 2018 | OncLive

Ardaman Shergill, MD, discusses the impact of tumor mutational burden, as well as RET and NTRK fusions, in the NSCLC paradigm.

Original Article: Novel Molecular Markers at Forefront of NSCLC Research

NEXT ARTICLE

More From BioPortfolio on "Novel Molecular Markers at Forefront of NSCLC Research"

Quick Search

Relevant Topic

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...